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Saudi ArabiaAbstract Objectives: The current study aimed to explore the knowledge, perception, and attitude
of physicians toward generic medicines in Saudi Arabia.
Background: The local market of generic medicine share in Saudi Arabia is low compared to
global and regional statistics. The reason for this low market share and the role of physicians
has not previously been investigated. The purpose of this study was to assess health practitioner
level of perceived knowledge, opinions and attitudes about local generic medication, and identify
factors that inﬂuence infrequency of generic prescriptions.
Methods: A random sample of 231 physicians was recruited from two hospitals in Riyadh (one
government one private) and 178 (77%) responded. Information on the physicians’ perceived
knowledge, opinions and attitude toward local generic medication was extracted, analyzed and
interpreted. Factors that inﬂuence infrequent prescription of local generic drugs were identiﬁed.
Results: Among the 178 participants in the physicians’ survey, 76% and 47% reported that they
are knowledgeable about the terms ‘‘generic’’ and ‘‘bioequivalence’’ respectively, while 44%
reported that they are able to explain bioequivalence to their patients. Approximately 52% of
physicians reported that local generics should be substituted for brands if suitable for the case,
398 H.O. Salhia et al.and 21.9% reported that they believe SFDA approved local generics are therapeutically equivalent
to their brands. Clinical effectiveness was reported by 71.9% of physicians as the most inﬂuential
factor effecting prescription of brand over local generic medication. The three independent signif-
icant predictors for infrequent prescription of local generics among physicians: Government sector
employment (OR = 3.74, [95%CI 1.50–9.43]), consultant level (OR= 3.94, [95%CI 1.50–10.31])
and low level of knowledge about local generics (OR = 4.11, [95%CI 1.56–10.84]).
Conclusion: The low market share of local generics medicines attributed to low prescription rates
is signiﬁcantly more among senior-level physicians working in governmental hospitals. Low level of
knowledge about generic drugs among physicians was the strongest predictive factor for low
prescription. Future bigger studies are needed to conﬁrm these results.
ª 2015 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The total healthcare budget in Saudi Arabia for 2012 was SAR
86 billion (Gamble, 2011), while the total drug consumption
was between SAR 13 and 14 billion. Of this total, 84% was
estimated to be primarily imported brand names and only
16% was local generics (Al Shaikh and Chahine, 2011).
According to the SFDA, a generic drug product is a pharma-
ceutical product that is interchangeable with an innovator
branded product, and is manufactured and marketed without
a license from the innovator company after expiry of the drug’s
patent and other exclusivity rights. When generic drug prod-
ucts become available they drive down prices of both the inno-
vator drug and its corresponding generics (Bioequivalence
Requirements Guidelines, 2005). The Saudi population is
expected to reach 30 million in 2015 (Al Shaikh and
Chahine, 2011). These demographics have driven overall
pharmaceutical expenditure to increase by around 10% from
2010 to 2012 (http://www.pressbox.co.uk/detailed/Business/
Generics_to_Scale_High_in_Saudi_Arabian_Pharmaceutical_
Market_664609.html, 2011) and is expected to continue
putting pressure on the Saudi economy in the future.
Globally, local generics account for more than 65% of the
pharmaceutical market share (Shrank et al., 2009; Al Shaikh
and Chahine, 2011). In the USA alone, $ 9 billion (11% of
total prescription costs) were saved during the period from
1997 to 2000 through the use of generic drugs (Fischer and
Avorn, 2003; Haas et al., 2005). In 2009, 66% of prescriptions
in the USA were for generic drugs that contributed to only
13% of total prescription expenditure (Shrank et al., 2009).
With over $100 billion worth of innovator drugs losing their
patent protection between 2010 and 2014, it is essential for
countries to develop their generic drug manufacturing capabil-
ities to take advantage of this new market (http://www.report-
linker.com/ci02261/Generic-Drug.html, 2012). According to
the WHO the 2009 total global annual cost of health services
was over US$4 trillion, of which US$750 billion was the total
expenditure on pharmaceuticals (WHO, 2009). According to
IMS Health market prognosis, the total global pharmaceutical
expenditure was estimated to grow by 4–5% in 2010 and 5–7%
in 2011 to reach US$ 880 billion (www.abpi.org.uk; Moon,
2005). These projections are consistent with the EFPIA statis-
tics which have global pharmaceutical sales in 2011 at US$ 856
billion (www.efpia.eu, Chidambaram, 2011; Market Analysis,
2012).A study conducted in the USA in 2005 (Barrett, 2005)
showed that 78% of physicians support generic substitution
in most cases, with 17% said they would prescribe generic
drugs in all cases when they are available. Only 5% pf doctors
indicated they did not support generic substitution. Ninety
percent of physicians surveyed believed they were knowledge-
able enough about generic bioequivalence to instruct informed
substitution of generics for brands. Sixty-nine percent indi-
cated that therapeutic index inﬂuenced their decision to pre-
scribe a brand over a generic, while 75% thought that
certain drugs that have a narrow therapeutic index should
never be substituted for generics (Barrett, 2005).
A similar study was conducted in Riyadh, Saudi Arabia
from May to September 2007 (Alghasham, 2009). Overall
79% of physicians said they supported generic substitution
in most cases, while 16% supported it in all cases where a gen-
eric is available and only 5% objected to their use entirely.
Ninety-six percent said they had enough knowledge about
the therapeutic value of generics to prescribe them in conﬁ-
dence. Seventy-two percent of physicians agreed that price dif-
ference inﬂuenced them to prescribe generics. The study also
found that 82% of doctors have perceived conﬁdence in pre-
scribing generic drugs that are approved governmentally
approved. However, 35% of doctors who participated in this
study indicated that ‘‘therapeutic failure’’ is a serious problem
with some generic drugs (Alghasham, 2009).
Theodorou et al. (2009) conducted a survey in 2007 in
Greece and Cyprus. Proven clinical effectiveness was found
to be the most inﬂuential factor for prescribing medication
for over 90% of physicians in both Greece and Cyprus.
Fifty-one percent of physicians in Greece and 60% of physi-
cians in Cyprus rated the quality of generic drugs compared
to brand name drugs to be satisfactory or excellent, while
54% in Greece and 68% in Cyprus rated safety of generic
products as satisfactory or excellent. Effectiveness of generic
drugs was rated as satisfactory or excellent by 52% of Greek
physicians and 62% of the physicians in Cyprus. Overall only
25% of physicians in Greece indicated that they prescribed
generic drugs instead of brand name drugs often or very often
versus 67% in Cyprus (Theodorou et al., 2009).
In Istanbul, Turkey a survey was conducted (Toklu et al.,
2012) among physicians and revealed that around 32% of
them believe that generic drugs did not differ from their brand
name originals. Eighty-two percent of physicians stated that
they were unsure about the bioequivalence of generic drugs
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generic drugs. Cost was identiﬁed as the most important factor
playing a role in their decision to substitute with a generic
(Toklu et al., 2012).
The aim of our study, which was conducted in Saudi Ara-
bia, is to understand the level of self-rated physician knowl-
edge, and their opinions and attitudes toward local generic
prescription. Since the last survey conducted on this subject
in Saudi Arabia in 2007 (Alghasham, 2009), the Saudi pharma-
ceutical market has gone through signiﬁcant changes. In 2005
when the total market size was SAR 6.23 billion, local generics
constituted around 20% of the market or SAR 1.25 billion
(Saudi Ministry of Planning and Economy, 2005). In 2013
the total size of the market had doubled (over SAR 13 billion)
and the size of the generic portion had doubled as well (around
SAR 2.5 billion) (Al Shaikh and Chahine, 2011). But the per-
cent market share of local generics over the 8 year period has
actually dropped from 20% to 16% (Aljazairi et al., 2008).
So an up-to-date survey is needed to ﬁnd out if there has been
a signiﬁcant shift in perceived knowledge and attitude as well.
Our study also aims to determine the concerns and limitations
that physicians have toward generic drug prescription, and
address the factors that inﬂuence physicians when deciding
to prescribe a brand or a generic.
2. Methods
2.1. Study design and setting
The study was conducted in ten medical departments ran-
domly selected by cluster sampling in two hospitals in Riyadh;
one government hospital (NGHA/National Guard Health
Affairs Hospital) and one private hospital (SGH or Saudi Ger-
man Hospital). A total population of 505 physicians was
requested to ﬁll the survey. The population included all physi-
cians currently working in any of the ten selected departments
in either of the two participating hospitals, of any education
level that has been practicing in Saudi Arabia for one year
or more. A cross sectional, self-administered questionnaire-
based study was conducted. Permission was taken from King
Saud bin Abdulaziz University for Health Sciences (KSAU-
HS) Collage of Public Health and Health Informatics (CPPHI)
Research and Ethics Committee for conducting this study, and
ethical approval was obtained from the King Abdullah Inter-
national Medical Research Centre (KAIMRC) Internal
Review Board prior to the actual study. The approval of the
CEO was obtained from each hospital.
2.2. Survey development and administration
A questionnaire on physician self-rated level of knowledge,
attitudes and opinions was self-developed. The questionnaire
was evaluated by qualiﬁed research supervisors from CPPHI
and KAIMRC. The survey was conducted from March to
May 2013 in the two hospitals after permission was obtained
from both CEOs. A list of the medical departments in the
two hospitals was obtained, arranged in alphabetical order
and numbered. Using cluster sampling technique, 10 depart-
ments were selected for the study. A list of all 231 physicians
in the selected departments was obtained and they were con-
tacted face to face or through the department secretary andinvited to ﬁll the questionnaire. Due to the initial low response
rate at NGHA we continued to follow up in person, through
the department secretaries and through the ofﬁce of the Head
of Medical Services until we reached our target sample size.
After applying exclusion criteria of ‘‘not less than one year
practicing in Saudi Arabia’’ the total number of ﬁlled question-
naires collected was 178 (62 from SGH at a response rate of
80% and 116 from NGHA at a response rate of 76%), giving
an overall response rate of 77%. Data were entered into SPSS
version 20 and reviewed by a colleague for accuracy.
2.3. Survey content
The questionnaire was designed to collect data on physicians’
self-perceived level of knowledge, opinions and attitudes
toward local generic medication prescription. It also gathered
information about concerns physicians have about the local
generic industry. The questionnaire was composed of 40 multi-
ple choice questions on Likert scale measurement and three
open ended questions, which we estimated would take around
15 min to complete. The questionnaire was divided into four
main parts:
Demographic variables; age, years of credential in general,
years of practice in Saudi Arabia, credential, medical specialty
and employment sector.
Physician perceived level of knowledge; Ten questions that
examined how physicians rate their level of knowledge about
the meaning of ‘‘generic’’ and ‘‘brand’’, bioequivalence, and
therapeutic bioequivalence. The questions also enquired about
awareness of price difference of generic compared to brand.
One open-ended question inquired about the most common
sources of physician’s knowledge about local generic
medication.
Physician opinions; Twelve questions investigated the opin-
ions of physicians on the variables of price range, effectiveness
and safety, quality, therapeutic equivalence to brand, availabil-
ity and diversity of pharmacological classes. In addition, this
section addressed the impact of regulations, insurance compa-
nies and hospital management on local generic prescription
rates. One open-ended question asked about which pharmaco-
logical classes of local generics have the biggest shortage.
Physician attitudes; Thirteen questions tackled factors that
affect physician’s decision to prescribe a generic medication.
These included variables like therapeutic failure, narrow ther-
apeutic index, effectiveness, dosage form, patient improve-
ment, generic side effects, cost difference and patient medical
insurance. One open ended question asked physicians about
cases in which they would never prescribe generics.
2.4. Statistical analysis
All data collected were entered manually into an Excel work-
sheet, then checked and screened for errors. Each variable
was coded and numbered. Predictive Analytics Software
(PASW formerly SPSS) version 20 (IBM, SPSS Inc., Chicago
IL, USA) was used for data analysis. Descriptive statistical
techniques were used to answer our descriptive research ques-
tions. Categorical variables were summarized using frequency
tables, pie and bar charts. Logistic regression analysis was used
to assess if there exists an association between infrequent pre-
scription of local generic drugs (as the dependent variable) and
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Table 2 Perceived knowledge of the participating physicians
about local generics.
Variable Number (%)
Range of price diﬀerence familiarity
Strongly disagree 23 (12.9)
Disagree 26 (14.6)
Neutral 42 (23.6)
Agree 53 (28.8)
Strongly agree 34 (19.1)
Ability to explain therapeutic BE to patients
Strongly disagree 23 (6.7)
Disagree 26 (17.4)
Neutral 42 (32.0)
Agree 53 (32.0)
Strongly agree 34 (11.8)
Source of knowledge about local generics
Medical Reps 81 (45.5)
Medical publication 35 (19.7)
Textbooks 25 (14.0)
Insurance company 2 (1.1)
Others 35 (19.7)
400 H.O. Salhia et al.the following independent variables: Employment sector, qual-
iﬁcation level, years of practice in KSA, opinion about The
Saudi Food and Drug Authority (SFDA) approved generic
drugs and level of knowledge. The logistic regression models
were ﬁrst ﬁtted with each of these variables separately to esti-
mate the univariate odds ratios (ORs). Then all independent
variables that were signiﬁcant at univariate level were included
in the multivariate regression equation to estimate the adjusted
OR for each of the variables. A P-value of at least 0.05 was
used to justify a claim of statistically signiﬁcant effect.
3. Results
Female doctors represented 37% of our surveyed population.
Almost half of the study population was consultants and about
two thirds of the participants worked in a government hospital
(Table 1).
Approximately three quarters of the study population
either agreed or strongly agreed that they were familiar with
the terms ‘‘generic medication’’ and/or ‘‘brand medication’’.
Around half of the study population stated that they either
agreed or strongly agreed that they were familiar with the term
‘‘Bioequivalence Process’’ and/or the price difference between
brand and generic medication. Less than half of the study pop-
ulation (n= 87, 43.8%) stated that they were able to explain
therapeutic bioequivalence to patients. Medical representatives
were perceived by the participating physicians to be their main
source of knowledge about local generics (n= 81, 45.5%)
(Table 2).
Fig. 1 summarizes opinion of participating physicians’ in
relation to prescribing local generic medications. The percent-
age of physicians who agreed to prescribe local generics (38%)
was higher than that who disagreed (22%), while the rest had
neutral opinion. Higher percentages of physicians acknowl-
edged that the price of generics is low while prices of brandFig. 1 Physicians opinion and attitude toward the prescription
of local generic drugs (N= 178).
Table 1 Characteristics of the study population (N= 178).
Variable Number (%)
Gender
Male 112 (62.9)
Female 66 (37.1)
Total years of practice
1–5 39 (21.9)
6–10 30 (16.9)
11–15 31 (17.4)
16–20 39 (21.9)
>20 39 (21.9)
Years of practice in KSA
1–5 80 (44.9)
6–10 35 (19.7)
11–15 25 (14.0)
16–20 22 (12.4)
>20 16 (9.0)
Credential
GP 39 (21.9)
Specialist 58 (32.6)
Consultant 81 (45.5)
Employment sector
Governmental 116 (65.2)
Private 62 (34.8)medications are high. When comparing the quality and effec-
tiveness of local generic medication to that of brand medica-
tion, less than one third of the physicians agreed that they
were comparable. For safety on the other hand 38.2% agreed
on the comparable safety of local generic medication com-
pared to their corresponding brands. Regarding the therapeu-
tic equivalence of SFDA approved local generic medications to
their corresponding brand medications 21.9% agreed that they
were therapeutically equivalent, while the rest of physicians
either disagreed or had a neutral opinion.
Fig. 2 presents opinions of physicians about the impact of
local regulations and the availability of local generic medica-
tion. More than one third of the participating physician’s
agreed that there were sufﬁcient quantity of drugs that favor
local generic prescription. Less than one third agreed that hos-
pital administration put pressure for prescribing local generics.
17.40%
24.20%
14%
42%
28.70%27.50%
24.20% 23%
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22.50%
Medical insurance 
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Hospital 
administraons 
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Fig. 2 Physicians opinion with respect to the impact of local regulation and availability of local generic medications (N= 178).
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insurance companies for prescribing speciﬁc drugs.
Our study also showed that half of the participating physi-
cians (n= 90, 50.6%) indicated that they prescribed local gen-
eric medications daily. Less than one third that was 26.4% of
participants agreed or strongly agreed that there was a serious
problem with therapeutic failure of local generics. Regarding
the existence of cases where local generic drugs must never
be prescribed 37% agreed that this was true. However 43.3%
indicated that they were neutral.
Participating physicians believed there was a shortage in the
supply of local generic medication in a number of pharmaco-
logical classes such as antidepressants and antipsychotics,
which was reported by 10.67% followed by enzymes and hor-
mones which was reported by 9.55% and anti-hypertensive
which were reported by 8.43%. Also, the study addressed the
cases where practicing physicians never prescribed local gener-
ics. 7.87% named serious infections as the most common cases
where they would never prescribe local generic medication fol-
lowed by emergency and/or terminal cases which were
reported by 5.625% and cardiac cases and cardiac surgeries
which were reported 5.06%.41% 
71.90% 
43.80% 
64.60% 
48.90% 
45.50% 
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44.40% 
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Fig. 3 Bar-chart illustrating percentage of participants who
agree or strongly agree on factors that inﬂuence prescription of
generic drugs (N= 178).Fig. 3 summarizes the results of the survey questions related
to the factors that inﬂuence physician prescription decisions.
The most inﬂuential factor according to the survey was clinical
effectiveness, followed by patient improvement, where 71.9%
and 64.6% respectively, agreed or strongly agreed that these
factors were inﬂuential. The least inﬂuential factor was patient
medical insurance coverage, which only 31.50% agreed was
inﬂuential in the prescription decision making process.
Table 3 shows the results of the univariate and multivariate
logistic regression analysis. The univariate analysis indicates
that physicians working for the governmental sector are 5.48
times more likely to be infrequent prescribers of local generic
medication than physicians working for the private sector. In
addition, consultants are 2.63 times more likely than specialists
to be infrequent local generic prescribers. Also physicians with
6 or more years of practice in KSA are twice as likely to be
infrequent prescribers as those who have worked in KSA for
1–5 years. Finally the univariate analysis indicates that physi-
cians with low level of knowledge about generic medication
are 3 times more likely to be infrequent prescribers than those
with high level of knowledge about generic medication. The
multivariate analysis shows that the signiﬁcant independent
predictive factors for infrequent prescription of local generic
medication were government sector employment (OR =
3.74, [95%CI 1.50–9.43]), consultant level qualiﬁcation
(OR= 3.94, [95%CI 1.50–10.31]) and low level of knowledge
about generic medication (OR= 4.11, [95%CI 1.56–10.84]).
Years of practice in KSA and opinion about therapeutic equiv-
alence of SFDA approved local generic medications, become
insigniﬁcant at multivariate level. Also, opinion of physicians
about therapeutic equivalence of SFDA approved local generic
medications was not predictive of infrequent prescribing of
local generics (OR = 0.51, [95%CI 0.20–1.30]).
4. Discussion
This study showed that a majority of physicians perceived
themselves to have good knowledge of the terms generic,
brand and bioequivalence, but they have less ability to explain
the meaning of bioequivalence to their patients (Table 2).
Compared to a USA study conducted in 2005 (Barrett, 2005)
where 86% of physicians reported that they could explain bio-
equivalence to their patients, only one half of that percentage
Table 3 Summary of logistic regression Analysis for variables predicting infrequent prescribing of local generic medications
(N= 178).
Factors Univariate analysis OR (95% CI) Multivariate analysis OR (95% CI)
Employment sector
Private (Ref) 5.48(2.39–12.55) 3.74(1.50–9.42)
Governmental
Credential
Specialist (Ref) 1.54(0.62–3.85) 0.98(0.34–2.82)
GP 2.63(1.24–5.62) 3.94(1.50–10.31)
Consultant
Years of practice in KSA
1–5 yrs (Ref) 2.07(1.08–3.95) 1.27(0.54–2.99)
6 yrs or more
Opinion about that SFDA
Equivalent to brand drugs (Ref) 1.02(0.48–2.17) 0.51(0.20–1.30)
Approved generic drugs
Level of knowledge
High Level (Ref) 0.85(0.39–1.87) 1.16(0.48–2.79)
Moderate 3.11(1.41–6.83) 4.11(1.56–10.84)
Low
The bold indicates statistical signiﬁcance at a P-value level of 0.05.
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This could be due to a lack of knowledge, or a lack of motiva-
tion on the part of our physicians to explain details to patients
who in many cases are uneducated or old. Or it could be due to
the difference in culture and malpractice regulations between
the USA and Saudi Arabia that force USA physicians to
explain all medication details to their patients.
Almost one half of physicians in our study perceived that
they knew about the price difference between brand and gen-
eric medication. This is much lower than ﬁgures reported in
previous studies in the USA (73%) (Barrett, 2005) and in
Saudi Arabia (75%) (Alghasham, 2009). The reason for this
drop in awareness could be that with patients obtaining treat-
ment either from a government hospital or through an insur-
ance company, physicians do not feel the need to ﬁnd the
most economical medications for their patients.
Our surveyed physicians in this study also perceived that
medical representatives were the most common source of
knowledge about generic medications, while in the USA health
insurers and pharmacy beneﬁt managers were the most com-
mon source of knowledge about generic drugs (Barrett,
2005). This is also an indicator that as medical insurance reg-
ulations mature in Saudi Arabia the inﬂuence of insurance
companies should increase like in the USA, and they should
be more proactive in promoting local generic medication. Only
1.1% of our surveyed physicians stated that they received the
information from insurance companies.
Our study revealed that about half of the physicians sur-
veyed believed that local generics should be prescribed if they
were available and suitable for the case. This number is less
than both of the similar previous studies conducted in the
USA (Barrett, 2005) and Saudi Arabia (Alghasham, 2009)
which both reported this ﬁgure at around 80%. The conﬁdence
of our study sample in local generic drugs is lower than what
we expected after conducting our literature review. This lower
conﬁdence could lead to lower prescription rates of local
generics.Among our study population the number of physicians who
thought that local generics were not comparable to brand
name drugs in quality and effectiveness was higher than the
number who thought they were comparable. Regarding safety
the numbers that believed generics were comparable to brands
were similar to the numbers who believed they were not com-
parable. However for quality, effectiveness and safety the high-
est response rate was for the neutral group which indicated
that there could be a lack of knowledge about therapeutic bio-
equivalence of generic drugs among participating physicians.
In contrast more than 60% of physicians surveyed in Cyprus
(Theodorou et al., 2009) believed that the efﬁcacy, safety and
effectiveness of generic medication were comparable to the
corresponding brand.
Only one ﬁfth of the physicians that participated in our sur-
vey agreed that the local generic medications approved by the
SFDA were therapeutically equivalent to their corresponding
brand. In the USA exactly double this number (Barrett,
2005) agreed that FDA approved drugs were equivalent to
their brand counterparts. This opinion could be due to a fun-
damental lack of trust in the SFDA approval process among
physicians in Saudi Arabia. Despite this our study still showed
that half of the participating physicians prescribed local gener-
ics on a daily basis.
A small proportion of participating physicians felt pressure
from regulators, insurance companies or hospital administra-
tors to prescribe more local generics. In the USA more than
80% of physicians (Barrett, 2005) said that they felt they were
encouraged by healthcare authorities, insurance companies or
pharmacy beneﬁt management companies to prescribe more
local generics. Governmental healthcare authorities and medi-
cal insurance companies should introduce measures that
encourage physicians to prescribe more local generic medica-
tion. Almost all of the medication prescribed in Saudi Arabia
is either dispensed in a governmental medical facility or in a
private medical center through a medical insurance company.
Government regulators and medical insurance companies are
Perception and attitude of physicians towards local generic medicines 403both major players in promoting the increased market share of
local generics.
Our study indicated that clinical effectiveness was the most
inﬂuential factor for more than 70% of participating physicians
when prescribing a brand over a generic. This is similar to a
study in Greece and Cyprus (Theodorou et al., 2009) that
showed that clinical effectiveness was the most important fac-
tor for over 90% of physicians when deciding to prescribe a
brand over a generic. On the other hand, the factor that was
reported as least inﬂuential among our study sample was nar-
row therapeutic index, which was mentioned as inﬂuential by
only 40% of participants. In the USA study (Barrett, 2005) nar-
row therapeutic index was indicated as inﬂuential by more than
two thirds of participating physicians. This result could be an
indicator for lack of knowledge about the meaning of narrow
therapeutic index medication among our study population.
Around one third of the physicians participating in our sur-
vey indicated that there were speciﬁc cases when they would
never prescribe generic medication. The cases mentioned most
frequently were serious infections. Also about two thirds of the
study population indicated that there were speciﬁc pharmaco-
logical classes where they had experienced a shortage of local
generic medication in their practice. The highest pharmacolog-
ical class mentioned was antidepressants and antipsychotics,
followed by enzymes and hormones then anti-hypertensive.
Working in the governmental sector, physicians with low
level of knowledge were found to be predictors of infrequent
prescribing of local generic medication among our study pop-
ulation. Awareness among governmental hospitals is needed to
motivate physicians to prescribe more local generic medica-
tions. Consultants need to be approached and encouraged to
prescribe more local generics, however manufacturers and reg-
ulators should ﬁnd a way to increase their conﬁdence in gen-
eric medication. In general, there is a need to increase the
overall level of knowledge about local generic products among
physicians.
We have gathered information about the perceived knowl-
edge, opinion and attitude toward local generic medication
among physicians using a self-developed questionnaire. Given
that physicians are difﬁcult to recruit as study subjects, we were
able to reach the target sample size for the population, but only
because we anticipated a low response rate from the NGHA
physicians and distributed 231 questionnaires. The response
rate in our study was acceptable (77%). However, like any other
survey, non-participation bias is possible if those who did not
participate have different levels of knowledge and beliefs.
Another limitation in our research was that the sample all
came from two general hospitals which have drug formularies
that limit the range of drugs that physicians have to choose
from. Even though physicians were asked to respond based
on their perceived knowledge, opinions and attitudes there is
a risk that their responses are biased by the drug formularies
that they have to use in their daily practice. This bias may have
a negative impact on the reliability and validity of the survey
results, and therefore affect our ability to generalize the results
to the whole population.5. Conclusion
The most important factors that inﬂuence infrequent prescrib-
ing of local generic medications by physicians are low level ofknowledge about local generics, working in a governmental
hospital and at a consultant level. Future bigger studies should
conﬁrm such results and focus on suggesting ways to address
these three factors by increasing overall physician awareness
and knowledge in governmental hospitals, and by improving
conﬁdence in local generic products.
Acknowledgements
We would like to acknowledge Kind Abdullah International
Medical Research Center for ﬁnding this study. We are very
thankful for the physicians who took part of this survey and
completed the questionnaires.
References
Alghasham, A.A., 2009. Generic drug prescribing in central Saudi
Arabia: perceptions and attitudes of physicians. Ann Saudi Med.
29 (1), 24–29.
Aljazairi, A.S., Balhareth, S., Eqtefan, I.S., Al-suwayeh, S., 2008.
Brand and generic medications: are they interchangeable? Ann
Saudi Med. 28 (1), 33–41.
Al Shaikh, S.A., Chahine, P., 2011. In-Focus Report, Saudi Pharma-
ceuticals Sector Review, Jeddah Saudi Arabia. National Commer-
cial Bank Economics Department, vol. 2. pp. 9–8
Barrett, L.L., 2005. Physicians’ Attitudes and Practices Regarding
Generic Drugs, Washington DC, AARP Knowledge Management,
33p. <http://assets.aarp.org/rgcenter/health/phys_generic.pdf>.
Bioequivalence Requirements Guidelines, Riyadh Saudi Arabia, the
Saudi FDA, 2005. <http://old.sfda.gov.sa/NR/rdonlyres/
6A114B70-4201-46EF-B4C7-127FD66D3314/0/BioequivalenceRe-
quirementGuidelines.pdf.
Fischer, M.A., Avorn, J., 2003. Economic consequences of underuse of
generic drugs: evidence from Medicaid and implications for
prescription drug beneﬁt plans. Health Serv. Res. 38, 1051–1063.
Chidambaram, A., 2011. What lures the attention of global generic
drug makers towards China? (Frost & Sulivan, internet) 2011, Aug
12 (cited 2013 March 7). <http://www.frost.com/sublib/display-
market-insight-top.do?id=240018520>.
Gamble, P., 2011. Saudi Arabia’s 2012 Budget, Riyadh Saudi Arabia,
Jadwa Investment. 26, 9p. <http://www.bttrading.org/downloads/
Saudi%20Arabian%20Budget%202012.pdf>.
Global Pharmaceutical Industry and Market (Association of the
British Pharmaceutical Industry ABPI, Internet) 2012 March (cited
2013 March 6). <http://www.abpi.org.uk/industry-info/knowl-
edge-hub/global-industry/pages/industry-market-.aspx>.
Haas, J.S., Phillips, K.A., Gerstenberger, E.P., Seger, A.C., 2005.
Potential savings from substituting generic drugs for brand-name
drugs: medical expenditure panel survey, 1997–2000. Ann. Intern.
Med. 142 (11), 891–897.
Market Analysis (Generics and Biosimilar Initiatives Online) 2012
November 14 (cited 2013 March 8). <http://www.gabionline.net/
layout/set/print/content/view/full/2211>.
Moon, M., 2005. How Beneﬁciaries Fare under the New Medicare
Drug Bill. Potential Savings from Substituting Generics for Brand-
Name Drugs. Ann. Intern. Med. 142 (11), 896. www.annals.org
Downloaded From: <http://annals.org/on 11/04/2014Common-
wealth Fund>. June 2004. Available at <www.cmwf.org/usr_doc/
moon_medicarerxdrug_ib_730.pdf>.
Saudi Ministry of Planning and Economy, Central Department of
Statistics, 2005.
Shrank, W.H., Cox, E.R., Fisher, M.A., Mehta, J., Choudhry, N.K.,
2009. Patients’ perceptions of generic medications. Health Aff. 28
(2), 546–556.
The Pharmaceutical Industry in Figures, Brussels Belgium, European
Federation of Pharmaceutical Industries and Associations
404 H.O. Salhia et al.(EFPIA), Key Data 2012, 28p. <http://www.efpia.eu/sites/www.
efpia.eu/ﬁles/EFPIA%20Figures%202012%20Final.pdf>.
Theodorou, M., Tsiantou, V., Pavlakis, A., Maniadakis, N., Fragou-
lakis, V., Pavi, E., Kyriopoulos, J., 2009. Factors inﬂuencing
prescribing behaviour of physicians in Greece, and Cyprus: results
from a questionnaire based survey. Ann. Intern. Med. 142 (11),
891–897.Toklu, H.Z., Du¨lger, G.A., Hıdırog˘lu, S., Akici, A., Yetim, A.,
Gannemog˘lu, H.M., Gu¨nes, H., 2012. Knowledge and attitudes of
the pharmacists, prescribers and patients toward generic drug use
in Istanbul – Turkey. Pharm. Practice 10 (4), 199.
WHO, The WHO Factsheet No 335, (internet), 2009 December, (cited
on 2012 August 3), <http://www.who.int/mediacentre/factsheets/
fs335/en/>.
